occurred. Miosis did not respond to intracameral adrenaline irrigation. Although we performed nucleus emulsification successfully, posterior capsule rupture developed during cortical cleaning. Vitreous loss was not present. A foldable intraocular lens was implanted into the sulcus.
Despite well-documented adverse effects, and the advent of a new generation antipsychotic drugs, chlorpromazine remains one of the most commonly used and inexpensive treatments for people with schizophrenia. 4 It has antagonistic effects on a 1 ARs, serotonin 5-HT 2 receptors, and dopamine D 1 and D 2 receptors. Its a 1 AR-blocking activity is very prominent, and is responsible for some of the side effects including orthostatic hypotension, high-resting pulse rates, and impotence. 5 We believe that the most likely cause for IFIS in this patient was chronic chlorpromazine use. a 1 ARs predominate in sympathetically mediated iris dilator muscle contraction resulting in mydriasis. Long-term blockade of these receptors by chlorpromazine may prevent mydriasis and result in dilator muscle tone loss. We are not sure whether the occurrence of IFIS would be prevented or not if chlorpromazine had been stopped before surgery. Disuse atrophy may have developed in this patient because of long-term use of an a 1 AR antagonist. Anyway, we suggest that discontinuation of chlorpromazine might be a wise course of action before cataract surgery to avoid the possibility of IFIS.
Sir, Vitreous and aqueous penetration of orally administered moxifloxacin in humans We would like to comment on the above paper by Vedantham et al. 1 The authors state that 'the spectrum of coverage does not appropriately encompass the most common causative organisms in endophthalmitis, especially Staphylococcus epidermidis'. This is based on the assumption that the MIC 90 of moxifloxacin for Staph. epidermidis is 2 mg/ml (Table 1) . 2 This is contrary to other publications on MIC 90 tables for moxifloxacin. [3] [4] [5] Published susceptibility tables for moxifloxacin include pathogens isolated from systemic infections and therefore are not representative of endophthalmitis pathogen susceptibilities. When these were examined, the great majority of Staphylococci were susceptible to moxifloxacin. 6, 7 The authors also state that they decided to test moxifloxacin because of its low MICs against pathogens implicated in endophthalmitis (including Gram-positive bacteria), which is contrary to the MICs in Table 1 that they use for their analysis.
Of notice also are the wide variations of moxifloxacin concentrations in aqueous and vitreous samples in their series. These are contrary to other studies, [8] [9] [10] [11] where moxifloxacin achieved very steady concentrations for at least 12 h after oral administration. Their serum concentrations also are variable and in a few cases extremely low, which is not in accordance with bibliography on serum moxifloxacin levels, [3] [4] [5] although the usual dose is the same as the one used by the authors (400 mg OD). The authors attribute (in part) low levels of moxifloxacin to the fact that only one dose of 400 mg was administered to 'simulate the clinical scenario'. In general, whenever intraocular penetration of a systemically administered antibiotic is to be determined, higher loading doses are used and in the case of moxifloxacin no hazardous side effects were noted previously.
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In conclusion, we mention that the results of this paper should be interpreted with caution and that there are numerous data suggesting that moxifloxacin may be a very useful systemic addition in endophthalmitis treatment. The following are our responses to their comments:
(1) Kampougeris et al mention that other publications have found majority of staphylococci to be susceptible to moxifloxacin. We too have noted this in our paper. In fact, this was the main reason that prompted us to design the study. The low intraocular concentrations found in our study in contrast to other publications surprised us as well, but we have given reasons that might explain the same in our paper. (2) Kampougeris et al state that we decided to test moxifloxacin because of its low minimum inhibitory concentrations (MICs) against pathogens implicated in endophthalmitis, which is contrary to the MICs in Table 1 that we had used for analysis. We had in fact mentioned that the MIC 90 of moxifloxacin was lower than that for the other fluoroquinolone antibiotics against the pathogens responsible for endophthalmitis and had quoted Table 1 as the reference. 2 Hence, we take issue with the statement that we are contradicting ourselves. (3) Kampougeris et al also mention about the wide variations in the moxifloxacin levels in our series. We have clearly discussed about this in our study: 'Amongst the serum, aqueous, and vitreous concentrations, there appeared to be several values that were considered outliers. We chose to include all data obtained in the study, as the investigators could not explain these high or low concentrations and attributed them to variability of moxifloxacin pharmacokinetics in individual patients.' (4) Kampougeris et al also mention that these variations were not seen in other similar studies. Of note, similar outlier values were noted by Hariprasad et al 3 in their series, and here too the authors attributed these to inter-patient variability of drug pharmacokinetics. (5) They also seem to suggest that certain sampling errors occurred owing to processing delay. We consider this speculation unfortunate and unwarranted and we are disappointed at the suggestion, as we had ensured that all the samples were processed appropriately. The processing was as per our previous publication.
4 (6) Kampougeris et al also mention that the results of our paper have to be interpreted with caution. We too have not claimed so and have mentioned the need for future studies in our paper.
